Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
kylo-12
- Development stage
- Phase 1
- Lead developer
- Kylonova Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Kylo-12 is an investigational drug developed by Kylonova (Xiamen) Biopharma, currently in Phase 1 clinical trials. It is a small interfering RNA (siRNA) therapeutic designed to inhibit apolipoprotein C3 (APOC3), a key regulator of triglyceride metabolism. By targeting APOC3, Kylo-12 aims to reduce plasma triglyceride levels and improve lipid profiles, making it a potential treatment for hypertriglyceridemia and related lipid disorders. The first-in-human studies are evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity in healthy adult subjects[1][2][3][4].
- Brand names
- KYLO-12KYLO12KYLO 12
- Other names
- KYLO-12KYLO12KYLO 12
02
Targets
APOC3 (Apolipoprotein C-III)
Beyond the preview
Go deeper on kylo-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on kylo-12.